3-(1-Piperazinyl)-1,2-benzisothiazoleCAS# 87691-87-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 87691-87-0 | SDF | Download SDF |
| PubChem ID | 2772144 | Appearance | Powder |
| Formula | C11H13N3S | M.Wt | 219.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-piperazin-1-yl-1,2-benzothiazole | ||
| SMILES | C1CN(CCN1)C2=NSC3=CC=CC=C32 | ||
| Standard InChIKey | KRDOFMHJLWKXIU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C11H13N3S/c1-2-4-10-9(3-1)11(13-15-10)14-7-5-12-6-8-14/h1-4,12H,5-8H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
3-(1-Piperazinyl)-1,2-benzisothiazole Dilution Calculator
3-(1-Piperazinyl)-1,2-benzisothiazole Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.56 mL | 22.7998 mL | 45.5996 mL | 91.1993 mL | 113.9991 mL |
| 5 mM | 0.912 mL | 4.56 mL | 9.1199 mL | 18.2399 mL | 22.7998 mL |
| 10 mM | 0.456 mL | 2.28 mL | 4.56 mL | 9.1199 mL | 11.3999 mL |
| 50 mM | 0.0912 mL | 0.456 mL | 0.912 mL | 1.824 mL | 2.28 mL |
| 100 mM | 0.0456 mL | 0.228 mL | 0.456 mL | 0.912 mL | 1.14 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isomagnolol
Catalog No.:BCN8325
CAS No.:87688-90-2
- Pentoxyresorufin
Catalog No.:BCC6297
CAS No.:87687-03-4
- 6-Hydroxyrubiadin
Catalog No.:BCN4425
CAS No.:87686-86-0
- Trandolapril
Catalog No.:BCC5275
CAS No.:87679-37-6
- RO-9187
Catalog No.:BCC1904
CAS No.:876708-03-1
- RF 9
Catalog No.:BCC7744
CAS No.:876310-60-0
- Montixanthone
Catalog No.:BCN8069
CAS No.:876305-36-1
- Ptaquiloside
Catalog No.:BCN8159
CAS No.:87625-62-5
- Smyrindioloside
Catalog No.:BCN4423
CAS No.:87592-77-6
- (+)-Lyoniresinol 9'-O-glucoside
Catalog No.:BCN4832
CAS No.:87585-32-8
- LXR-623
Catalog No.:BCC4273
CAS No.:875787-07-8
- cis-3,4-Dihydroxy-beta-ionone
Catalog No.:BCN6694
CAS No.:875666-39-0
- Alismoxide
Catalog No.:BCN1265
CAS No.:87701-68-6
- GPBAR-A
Catalog No.:BCC6201
CAS No.:877052-79-4
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
- H-Tyrosinol
Catalog No.:BCC2697
CAS No.:87745-27-5
- Bryostatin 2
Catalog No.:BCC5619
CAS No.:87745-28-6
- Tandospirone
Catalog No.:BCC4208
CAS No.:87760-53-0
- ML 221
Catalog No.:BCC6278
CAS No.:877636-42-5
- Eupalinolide B
Catalog No.:BCN2525
CAS No.:877822-40-7
- Eupalinolide A
Catalog No.:BCN2524
CAS No.:877822-41-8
- erythro-Guaiacylglycerol beta-sinapyl ether
Catalog No.:BCN6605
CAS No.:877875-96-2
- TW-37
Catalog No.:BCC2257
CAS No.:877877-35-5
- 6beta-Hydroxyipolamiide
Catalog No.:BCN4426
CAS No.:87797-84-0
Implications of N-capped urea/thiourea and C-capped 3-(1-piperazinyl)-1,2-benzisothiazole with bridging Gly-Val/Phe-Gly-Val-Pro as therapeutic targets.[Pubmed:25305332]
Eur J Med Chem. 2014 Nov 24;87:657-61.
A series of urea/thiourea derivatives were synthesized by using peptides conjugated to 3-(1-Piperazinyl)-1,2-benzisothiazole and their structure was characterized by analytical and spectral ((1)H, (13)C NMR and Mass) methods. These compounds were screened for antimicrobial and antiglycating activity as well as urease and H(+)/K(+)-ATPase inhibition. Preliminary structure-activity relationship studies revealed that the compounds possessing fluoro moiety were excellent antimicrobial agents. Furthermore, for other biological activities methoxy substituent was found to be the most active particularly upon substitution at para position.
Novel urea and thiourea derivatives of thiazole-glutamic acid conjugate as potential inhibitors of microbes and fungi.[Pubmed:25696935]
Bioorg Khim. 2013 Nov-Dec;39(6):736-44.
Since discovery and development of effective as well as safe drugs has brought a progressive era in human healthcare that is accompanied by the appearance of drug resistant bacterial strains, there is constant need of new antibacterial agent having novel mechanisms of action to act against the harmful pathogens. In the present study, several N-terminal substituted urea/thiourea derivatives were synthesized by the reaction of glutamic acid and 3-(1-Piperazinyl)-1,2-benzisothiazole with various substituted phenyl isocyanates/isothiocyanates. Elemental analysis, IR, 1H NMR, 13C NMR and mass spectral data confirmed the structure of the newly synthesized compounds. The derivatives were investigated for their antibacterial and antifungal activities against various pathogens of human origin by agar well diffusion method and microdilution method. The preliminary antimicrobial bioassay reveals that the compounds containing fluoro and bromo as substituents showed promising antimicrobial activity.
Ureas/thioureas of benzo[d]isothiazole analog conjugated glutamic acid: synthesis and biological evaluation.[Pubmed:23589361]
Arch Pharm (Weinheim). 2013 May;346(5):359-66.
A series of urea and thiourea derivatives of glutamic acid conjugated to 3-(1-Piperazinyl)-1,2-benzisothiazole were synthesized, spectroscopically characterized, and evaluated for their in vitro antiglycation and urease inhibitory activities. Preliminary screening of the synthesized compounds 1-35 showed significant results. Amongst these, compounds 17-21 and 30-35 bearing fluoro and methoxy substituents, respectively, exhibited inhibitory potency greater than the reference standards. Hence, they may serve as new lead compounds for further development.
